Decoy Therapeutics (NASDAQ:DCOY) Short Interest Down 57.7% in August

Decoy Therapeutics (NASDAQ:DCOY) was the recipient of a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 10,675 shares, a drop of 57.7% from the July 30th total of 25,246 shares. Based on an average daily trading volume, of 34,121 shares, the short-interest ratio is presently 0.3 days. Currently, 1.7% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, June 12th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Decoy Therapeutics presently has an average rating of “Hold” and an average target price of $30.00.

Decoy Therapeutics Trading Down 2.4%

Shares of NASDAQ:DCOY traded down $0.07 during trading on Friday, hitting $2.90. 33,351 shares of the company were exchanged, compared to its average volume of 27,218. The firm has a fifty day moving average price of $4.93 and a two-hundred day moving average price of $6.20. Decoy Therapeutics has a fifty-two week low of $2.85 and a fifty-two week high of $70.80. The stock has a market cap of $1.91 million, a price-to-earnings ratio of -0.10 and a beta of 0.64.

Decoy Therapeutics (NASDAQ:DCOY) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($4.46) EPS for the quarter. The business had revenue of $0.23 million for the quarter. As a group, research analysts predict that Decoy Therapeutics will post -12.97 EPS for the current year.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.